Humanigen expands partnership with Catalent biologics to manufacture investigational COVID-19 therapeutic candidate lenzilumab
Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent’s OneBio® integrated biologics suite expected to accelerate development, manufacturing and supply of